GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT

GlaxoSmithKline headquarters in London on Jan. 17, 2022. Hannah Mckay | Reuters UK pharmaceutical group GSK is in talks to acquire oncology biotech Nuvalent for more than $9 billion, in what would be the British drugmaker's largest acquisition in more than a decade, the Financial Times reported Tuesday. The companies have been in discussions with the aim of finalizing a deal as early as this week, the FT reported, citing people familiar with the matter. …